TELESTA THERAPEUTICS INC T.TST

"Efficacy and Safety of MCNA in Patients".... - Article

[Ghanam]

is available here: Researchgate

[Brouwie]

CONCLUSIONS: ''Our multicenter study demonstrates the signifi- cant activity of intravesical MCNA in patients at high risk in whom BCG failed. In this group, which included BCG refractory and BCG relapsing cases, the overall DFS rate was 25.0% at 1 year and 19.0% at 2 years. When substratified by risk category, MCNA achieved a 39.0% 1-year DFS rate in patients with BCG relapse and 35.1% in

[DamnYankees]

where and when was this article from? paraphrasing " safe effective alternative for those who are not candidates/refuse cystectomy". If they were limiting  the indication of BLA app to can't/ won't have cystectomy, that is essentially the closing line I would expect in the NR. I'll assume it's an old release as company has said nothing publicly since Adcomm

[Ghanam]

Ofcourse this is nothin new - it's the article for "The Journal of Urology" 04/15.

[DamnYankees]

Meaningless then. We all know the story on that rag

[Ghanam]

Well, you can get the article for free (shared by Dr. Morales)....that's the point. Normally it's payware ($30 or so).

[Tson99]

Thanks, Interesting how doctors specifically working in this field (Urology) came to these conclusions but the Adcomm panel could not. Kinda makes you wonder why they were there. Sound like a "no" is the default answer when you are not really sure how to vote. The Telesta team got caught flat-footed and failed to convince the panel. I still believe they thought this was a slam-dunk